STOCK TITAN
  1. Home
  2. Sec-filings
  3. KMTS
  4. [144] KESTRA MEDICAL TECHNOLOGIES, LTD. SEC Filing

Kestra Medical Technologies (KMTS) insider files to sell 8,759 shares under Rule 144

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. has a notice of proposed sale of common stock by insider Timothy Moran under Rule 144. The filing lists up to 8,759 shares of common stock to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $198,000.29 as of July 31, 2026. These shares relate to the vesting of performance share unit awards granted under the issuer’s equity compensation plan on July 17, 2026. The filing also reports that on July 30, 2026, Moran sold 4,117 shares of common stock for $93,758.64 within the past three months.

Positive

  • None.

Negative

  • None.
Shares proposed for sale 8,759 shares Common stock to be sold under Rule 144
Aggregate market value of proposed sale $198,000.29 Market value of 8,759 shares as of July 31, 2026
Recent shares sold 4,117 shares Common stock sold on July 30, 2026
Proceeds from recent sale $93,758.64 Value of 4,117 shares sold during the past three months
Vesting date of performance share units 07/17/2026 Vesting of performance share unit awards underlying the shares
Planned sale date reference 07/31/2026 Date associated with the proposed Rule 144 sale terms
Rule 144 regulatory
"notice of proposed sale of common stock by insider Timothy Moran under Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
performance share unit awards financial
"vesting of performance share unit awards granted under the issuer’s equity compensation plan"
equity compensation plan financial
"granted as part of issuer equity compensation plan on July 17, 2026"
A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FAQ

What does Kestra Medical Technologies (KMTS) disclose in this Rule 144 filing?
The filing discloses that Timothy Moran intends to sell up to 8,759 shares of Kestra Medical common stock under Rule 144, with an aggregate market value of $198,000.29 as of July 31, 2026.

How many KMTS shares are covered by Timothy Moran’s planned Rule 144 sale?
The notice covers up to 8,759 shares of Kestra Medical Technologies common stock. These shares are associated with vested performance share unit awards granted under the company’s equity compensation plan on July 17, 2026.

What prior KMTS stock sale is reported in the past three months section?
The filing reports that on July 30, 2026, Timothy Moran sold 4,117 shares of Kestra Medical common stock for total proceeds of $93,758.64, as part of the required disclosure of securities sold during the past three months.

What is the reported market value of the KMTS shares proposed to be sold?
The proposed sale of 8,759 shares of Kestra Medical common stock has a reported aggregate market value of $198,000.29 as of July 31, 2026, based on the pricing information included in the Rule 144 filing.

How were the KMTS shares in the Rule 144 filing originally obtained?
The shares relate to the vesting of performance share unit awards on July 17, 2026. These awards were granted as part of the issuer’s equity compensation plan, according to the securities information disclosed in the filing.

Which broker and market are involved in the KMTS Rule 144 sale?
The proposed sale will be placed through Merrill Lynch, located at 225 Liberty Street, New York, NY. The shares are Kestra Medical common stock listed for trading on the NASDAQ market, as noted in the securities information.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR